Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Natalia Plotnikova

Dermatology Boston, MA Medical Doctor

NPI 1114360575 CMS profile 2782825

800 Washington St, Boston, MA 02111

Open in the dashboard

General payments

$61,730

67 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Natalia Plotnikova of Boston, MA is reported in the CMS Open Payments database as having received $61,730 across 67 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $10,781 8
2021 General $12,199 11
2020 General $17,761 12
2019 General $20,989 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalia Plotnikova
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Natalia Plotnikova were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Natalia Plotnikova Dermatology median Middle half National median
2019 $20,989 $454 $129–$1,240 $163
2020 $17,761 $235 $81–$756 $114
2021 $12,199 $377 $108–$1,108 $132
2022 $10,781 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $57,959 60 payments
  2. Lilly USA, LLC $3,250 2 payments
  3. Galderma Laboratories, L.P. $290 2 payments
  4. Almirall LLC $119 1 payment
  5. Allergan Inc. $97 1 payment
  6. Genzyme Corporation $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,400 28 payments
  2. Travel and Lodging $4,363 12 payments
  3. Food and Beverage $1,953 25 payments
  4. Education $14 2 payments
Products named General payments · program years 2019–2022
  1. SKYRIZI $38,136 41 payments
  2. HUMIRA $18,922 18 payments
  3. RINVOQ $3,300 2 payments
  4. TALTZ $3,250 2 payments
  5. ORACEA $130 1 payment
  6. SOOLANTRA $130 1 payment
  7. Seysara $119 1 payment
  8. BOTOX COSMETIC $97 1 payment
  9. DUPIXENT $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

493

Median for Dermatology: 534

Drug cost

$324,059

Median for Dermatology: $67,151

Branded share of claims

25.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 47 $173,292
Taltz Autoinjector Ixekizumab Brand 11 $72,813
Jublia Efinaconazole Brand 29 $34,328
Xolair Omalizumab Brand 11 $26,947
Tacrolimus Generic 37 $6,412
Betamethasone Dipropionate Generic 36 $2,033
Fluocinolone Acetonide Generic 15 $1,681
Ketoconazole Generic 70 $1,217
Clobetasol Propionate Generic 40 $1,191
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 15 $976

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$18,618

Medicare's payments for the services billed

Medicare patients

133

Average age 74

Services billed

529

87 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 47%
Osteoporosis 34%
Diabetes 27%
Ischemic heart disease 27%
Cancer 23%
Chronic kidney disease 22%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

67 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record